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Introduction
For many years, parenteral administration of lipids aimed to
provide the organism with an efficient fuel and to prevent or
correct essential fatty acid deficiency (1). However, conven-
tional soybean oil-based fat emulsions contain great amounts
of linoleate (n-6) and insufficient amounts of antioxidants
such as -tocopherol (2). They lead to an accumulation of
linoleate in cell membrane phospholipids and are associated
with an increased production of peroxidative catabolites.
New preparations of lipid emulsions should be dedicated to
better maintain membrane fatty acyl balance (n-6/n-3 ratio)
and to stabilize or restore a suitable antioxidant status (2).
The ratio of n-6 and n-3 fatty acids in membrane phos-
pholipids affects structural and functional properties of the
cell membranes. Most importantly, n-3 fatty acids, namely
eicosapentaenoic acid (EPA), compete with n-6 arachidonic
acid to produce other lines of eicosanoids that are less
inflammatory and non-thrombogenic. The production and
release of various cytokines, interleukines and interferons
involved in immunoregulatory processes may be changed
by n-3 PUFA administration, too. Hence, it seems reason-
able to use fatty acids in order to modulate cell function and
metabolism (1–6). Indeed, supplementation with n-3 fatty
acids has been reported to improve various pathophysiolo-
gical states such as cardiovascular disease, psoriasis or
inflammatory bowel disease and is also expected to reveal
favourable effects in postoperative state, after injury or
during sepsis (2, 3). According to Tashiro et al. (7), adminis-
tration of n-3 polyunsaturated fatty acids (PUFA) improved
the stress response and modulated the immune status after
surgery. In postoperative patients a fast enrichment of plasma
and platelet phospholipids with EPA as well as effects on
mediator generation in leucocytes and platelets were reported
after intravenous administration of n-3 PUFA (8–10).
Fish oil was identified as a suitable source of very long-
chain n-3 PUFA. Since then, fish oil-containing lipid emul-
sions have proven to be well tolerated in humans, in terms of
usual clinical and metabolic parameters (2, 7, 8, 11–13).
However, information on the effects of fish oil-containing
lipid emulsions on the (anti)oxidativ status is scarce. Due to
the high degree of unsaturation EPA and DHA are much
more susceptible to oxidation than linoleic acid. Therefore,
fish oil-containing lipid emulsions are supplemented with
antioxidants such as -tocopherol to counteract peroxida-
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tion reactions. Regarding LCT emulsions which are low in
-tocopherol, their susceptibility to oxidation was shown
during storage (14–16) as well as after their infusion as
identified by an increased breath pentane production (17,
18) or a decreased number of enlarged LDL particles (19).
Contrary to this, in rats receiving TPN with a fish oil emul-
sion containing very high amounts of tocopherol homo-
logues, no hints for increased autoxidation reactions were
noted (20).
Therefore, the aim of the present study was to evaluate
the antioxidant status in surgical patients as affected by the
intravenous administration of two lipid emulsions largely
differing in their fatty acid pattern and -tocopherol content.
Materials and methods
Patients
Thirty-three adult patients with upper and lower gastro-
intestinal malignancies, adenomas (n = 2), or stenosis of the
small intestine (n = 1) who were undergoing major abdo-
minal surgery entered the study. Patients were eligible for
study entry when achieving the following criteria: no preg-
nancy, no lipid metabolism disorder (serum triacylglycerol
<250 mg/dl, serum total cholesterol <300 mg/dl), no severe
hepatic dysfunction, no severe blood clotting disorders, no
hemorrhagic necrotizing pancreatitis, no acute thrombo-
embolic events, no severe septic conditions. Characteristics
of the patients are given in Table 1.
The study was approved by the Ethics Committee of the
Medical Faculty of the University of Regensburg, and the
procedures followed were in accordance with the Helsinki
Declaration of 1975, as revised in 1989. All patients gave
informed consent before commencement of the investiga-
tion. The study was performed as a randomized, double-
blinded, and prospective trial between February and June
1997. Patients were randomly assigned to two groups
receiving an identical TPN regimen differing only in the fat
component.
TPN regimen
The nutrition regimen consisted of 1.33 g amino acids kg
body weight (bw)–1 d–1, 4.2 g glucose kg bw–1 d–1, and 1.4 g
fat kg bw–1 d–1, alltogether providing 35 kcal kg bw–1 d–1. As
a lipid component either a soybean oil emulsion (LCT;
Intralipid® 20%; Pharmacia GmbH, Erlangen Germany) or an
omega-3-fatty acid-containing fat emulsion (MLF, Lipoplus®
20%; B. Braun Melsungen AG, Melsungen, Germany) were
used. Fatty acid composition and antioxidant content are
given in Table 2. Fat emulsion (0.5 l) was added to 2 l
Nutriflex® plus (B. Braun Melsungen) to give an all-in-one
mixture. The mixture also provided sodium, potassium, cal-
cium, magnesium, chloride, and phosphate. Additionally,
trace elements and vitamins were administered. On the first
and second postoperative day, the TPN dose was restricted
to 50%. The TPN was delivered continuously over 22–24 h
per day on 5 consecutive days, beginning at the 1st post-
operative day in the morning (day 1) and ending at the 6th
postoperative day in the morning (day 6).
Blood sampling
Blood samples were drawn before surgery (day 0, fasted),
on the 1st postoperative day in the morning before starting
infusion (day 1, fasted), and on the 6th postoperative day in
the morning before the infusion was stopped (day 6, end
of infusion). Tubes containing the antioxidants EDTA
(1.6 mg/ml blood) and TROLOX (1 µmol/l blood; both
from Sigma, Deisenhofen, Germany) were used for blood
sampling. After plasma preparation the samples were stored
at –85°C until analysis.
Plasma lipids and plasma phospholipid fatty acid profile
Plasma total cholesterol, triglyceride and phospholipid con-
centrations were determined enzymatically using test com-
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Table 1 Characteristics of the patients
Group
MLF LCT
No. of patients 17 16
Mean age (y) 60.7 ± 8.7 59.4 ± 12.6
Sex (M/F) 10 / 7 13 / 3
Body height (m) 1.70 ± 0.09 1.71 ± 0.09
Body weight (kg) 74.9 ± 7.2 79.0 ± 13.8
Body mass index (kg/m2) 25.9 ± 2.5 27.0 ± 4.9
Operation procedures (n)
Gastrectomy 4 5
Resection of colon, rectum 11 10
Miscellaneous 2 1
Table 2 Ingredients, fatty acid composition, and antioxidant content of






Soybean oil 8.0 20.0
Omega-3-acid triglycerides 2.0 –
Phospholipids (egg yolk) 1.2 1.2
Glycerol 2.5 2.25
Fatty acid (wt.%) (mol-%) (wt.%) (mol-%)
8:0 30.1 40.7 – –
10:0 19.4 22.2 – –
14:0 0.5 0.4 0.2 0.3
16:0 5.9 4.7 10.5 11.2
16:1 0.6 0.5 0.1 0.1
18:0 2.4 1.7 3.7 3.6
18:1 7.9 5.7 20.9 20.3
18:2 n-6 24.4 17.7 56.6 55.2
18:3 n-3 3.3 2.4 7.8 7.7
20:5 n-3 3.1 2.1 – –
22:6 n-3 2.3 1.4 – –
Antioxidant (mg/l) (µgmol/l) (mg/l) (µgmol/l)
-Tocopherol 242.2~ 562.3~ 22.0 51.1
-Tocopherol 100.8 241.9 143.6 344.6
Ascorbyl palmitate 115.2~ 277.9~ – –
$MLF emulsion: Lipoplus®; #LCT emulsion: Intralipid®; ~Supplemented
by the manufacturer of the lipid emulsion, including naturally occurring
-tocopherol from soybean oil (range of 20–40 mg/l).
binations (‘Monotest Cholesterin’, ‘Triglyceride GPO-PAP’,
‘Test-Combination Phospholipide’; all Boehringer Mann-
heim GmbH, Mannheim, Germany).
After solvent extraction (21), the plasma lipids were sepa-
rated by means of thin layer chromatography (silica plates)
using petrol ether/ethylmethylketone/acetic acid = 84/15/1
(v/v/v) as solvent agent. Fatty acid methyl ester (FAME) of
phospholipids were obtained by transesterification with
TMSH (22). The FAME were separated by means of a CP-
Sil-88 capillary column (Chrompack, Frankfurt, Germany),
installed in an HP 5890 gas chromatograph with FID (Hewlett
Packard, Taufkirchen, Germany). For identification and
quantification of the FAME peaks, standard reagents of
analytical grade were used.
Determination of tocopherols, carotenoids, vitamin C,
selenium, and antioxidant capacity
Aliquots of the plasma samples before and after LDL-
apheresis were analysed for -tocopherol and carotenoid
concentrations by HPLC according to the described method
(23). Calculations were made using the internal standard
method and relative response factors. As internal standards,
-apo-8'-carotenoic acid ethyl ester and DL- -tocopheryl
acetate were added. Recovery of the substances after enrich-
ment of serum samples was within 94 and 107% with
coefficients of variation < 2.3% (n = 5).
Vitamin C content of plasma samples was analysed
photometrically (520 nm) according to Speitling et al. (24).
Ascorbic acid (Sigma, Deisenhofen, Germany) standard
solution was taken for calibration and quality control. Mean
recovery of ascorbic acid added to plasma samples (n = 7)
was 101.6% with a coefficient of variation of 0.7%.
Plasma selenium concentrations were determined by
graphite furnance atomic absorption spectrometry, using a
Perkin-Elmer 2380 atomic absorption spectrophotometer, a
HGA 500 graphite furnance as well as pyrolytically coated
graphite tubes with an inserted L'vov platform and a hallow-
cathode lamp for selenium (Perkin-Elmer, Überlingen,
Germany). Sample preparation and analysis conditions were
adapted from Welz et al. (25). Quality control was carried
out using Seronorm Trace Elements Serum (Promochem,
Wesel, Germany). Mean recovery of selenium (standard
solution) added to plasma samples (n = 4) was 96.9% with a
coefficient of variation of 6.7%.
Total antioxidant capacity of the serum samples was
measured with a chemiluminescent assay (26) using horse-
radish peroxidase (E.C. 1.11.1.7; Boehringer Mannheim
GmbH) and ELC immunoassay signal reagent (Amersham
International plc, Buckinghamshire, UK), providing lumi-
nol, p-iodophenol (enhancer) and hydrogen peroxide (oxi-
dant). Measurement of light emission was performed by
means of a Biolumat LB 9500 T (Laboratorium, Professor
Dr Berthold, Wildbad, Germany). Calibration was carried
out within each series using TROLOX (Sigma) standard
solutions and antioxidant capacity was expressed in µmol
TROLOX equivalent/l serum. Mean recovery of TROLOX
added to serum samples (n = 7) was 102% with a coefficient
of variation of 2.2%.
Analysis of cholesterol oxidation products (COP)
The plasma samples were analysed for the COP content in
their total cholesterol fraction. Cholesteryl esters were enzy-
matically hydrolyzed by cholesterol esterase (E.C. 1.1.1.13,
Sigma). The further methodology is described elsewhere in
detail (27). 5-Pregnen-3 -ol-7,20-dione (7-ketopregneno-
lone) was used as an internal standard. All standard sub-
stances were delivered by Steraloids Ltd (New Barnett, UK)
and Sigma. Identification of the sample peaks was made by
retention times of the standard substances and the character-
istic ion fragmentation. For quantification a selected ion
monitoring program was used. Recovery of free COP stan-
dard substances was in the range of 85 (cholestanetriol) –
123% (25-hydroxycholesterol); mean recovery for the sum
of COP was 99%. Mean coefficient of variation for the
determination of COP in plasma was 2.3% with a range of
1.9 (7 -hydroxycholesterol) – 5.3% (25-hydroxycholesterol).
Statistics
The results are given in terms of mean and standard error of
mean (SEM). Statistical analysis was performed with SPSS,
Version 7.5 (SPSS Inc., Chicago, USA). For analysis of
variance a two-factorial model with the factors ‘fat emul-
sion’ and ‘time’ was applied; comparisons of means were
made with the unpaired t-test at an -level of 5%.
Results
All patients enrolled completed the investigation; no ad-
verse drug reactions were noted. After 5 days of TPN with
the omega-3-fatty acid-containing fat emulsion, plasma
phospholipids contained a significantly higher portion of
eicosapentaenoic acid (2.07 mol-%) than found after admi-
nistration of the soybean fat emulsion (0.77 mol-%; Table 3).
The mean difference in docosahexaenoic acid (DHA) con-
centration between groups was not of statistical significance.
The mean portion of linoleic acid in plasma phospholipids
was significantly higher after administration of the LCT
emulsion compared to the MLF emulsion.
The plasma concentrations of selected antioxidants and
the total antioxidant capacity (TAC) are given in Table 4.
Statistically significant differences between groups were
found for -tocopherol and -tocopherol. Due to differences
in the mean carotenoid concentrations on day 0 and 1 be-
tween the two groups, the change during the infusion period
( day 6–day 1) was calculated. However, these values do
not indicate significantly different effects of the two fat
emulsions on carotenoids, vitamin C or selenium (Table 4).
Moreover, after correction for plasma lipids, only the
changes in plasma - and -tocopherol were found to be
significantly affected by the type of fat emulsion admi-
nistered (Table 5) but in both groups the decrease of TAC
values could not be stopped.
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Table 4 Antioxidant concentrations (mean ± SEM, µmol/l) and total antioxidative capacity (TAC, mol TROLOX-eq./l) in the plasma of surgical
patients before (day 0, fasted) and after surgery (day 1, fasted) as well as after 5 days of TPN (day 6, end of infusion) with an omega-3-fatty acid-containing
lipid emulsion (MLF; n=17) or an LCT emulsion (n=16)
Day 0 Day 1 Day 6 Day 6 – Day 1
MLF LCT MLF LCT MLF LCT MLF LCT
-Tocopherol 22.86 ± 1.45 25.57 ± 2.47 12.68 ± 0.75 13.49 ± 1.50 31.36 ± 1.69 16.18 ± 1.61 20.01 ± 1.60* 2.67 ± 1.01*
-Tocopherol 0.86 ± 0.13 0.86 ± 0.12 0.38 ± 0.07 0.43 ± 0.07 2.09 ± 0.20 3.78 ± 0.43 1.80 ± 0.21* 3.38 ± 0.41*
-Carotene 0.25 ± 0.04 0.50 ± 0.18 0.12 ± 0.02 0.21 ± 0.08 0.09 ± 0.02 0.22 ± 0.13 0.027 ± 0.008 0.005 ± 0.039
-Carotene 0.04 ± 0.01 0.07 ± 0.03 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.001 ± 0.001 0.001 ± 0.001
Lycopene 0.22 ± 0.04 0.46 ± 0.09 0.09 ± 0.02 0.20 ± 0.05 0.08 ± 0.02 0.17 ± 0.04 0.015 ± 0.009 0.051 ± 0.033
Lutein 0.15 ± 0.02 0.16 ± 0.02 0.08 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.07 ± 0.01 0.007 ± 0.003 0.009 ± 0.005
Cryptoxanthin 0.22 ± 0.06 0.18 ± 0.04 0.10 ± 0.03 0.08 ± 0.02 0.09 ± 0.03 0.06 ± 0.01 0.006 ± 0.005 0.008 ± 0.007
Carotinoids 0.88 ± 0.12 1.38 ± 0.24 0.40 ± 0.06 0.58 ± 0.10 0.34 ± 0.05 0.54 ± 0.15 0.06 ± 0.02 0.04 ± 0.07
Vitamin C 44.54 ± 3.66 43.80 ± 3.16 29.49 ± 1.94 32.51 ± 2.65 35.44 ± 5.73 25.10 ± 2.08 5.34 ± 6.47 7.57 ± 2.31
Selenium 0.65 ± 0.05 0.68 ± 0.06 0.43 ± 0.04 0.49 ± 0.04 0.50 ± 0.04 0.44 ± 0.04 0.06 ± 0.04 0.06 ± 0.03
TAC 320 ± 21 352 ± 25 265 ± 19 248 ± 14 153 ± 20 129 ± 12 99 ± 14 119 ± 18
*Significantly different means by treatment; P < 0.01; unpaired t-test.
Table 5 Plasma lipids and lipid-related antioxidant concentrations (mean ± SEM; mol, nmol antioxidant/µmmol plasma lipids#) in the plasma of surgical patients
before (day 0, fasted) and after surgery (day 1, fasted) as well as after 5 days of TPN (day 6, end of infusion) with an omega-3-fatty acid-containing lipid emulsion
(MLF; n=17) or an LCT emulsion (n=16)
Day 0 Day 1 Day 6 Day 6 – Day 1
MLF LCT MLF LCT MLF LCT MLF LCT
Triacylglycerol (mmol/l) 1.74 ± 0.16 1.66 ± 0.16 1.03 ± 0.12 0.95 ± 0.15 1.77 ± 0.16 1.29 ± 0.11 0.78 ± 0.15 0.54 ± 0.13
Total cholesterol (mmol/l) 5.55 ± 0.39 5.05 ± 0.33 2.97 ± 0.31 2.78 ± 0.24 3.50 ± 0.18 3.32 ± 0.27 0.59 ± 0.28 0.51 ± 0.19
Phospholipids (mmol/l) 2.98 ± 0.13 2.73 ± 0.12 1.80 ± 0.11 1.77 ± 0.11 2.46 ± 0.10 2.16 ± 0.12 0.68 ± 0.15 0.38 ± 0.10
Plasma lipids# (mmol/l) 10.27 ± 0.55 9.44 ± 0.57 5.80 ± 0.44 5.50 ± 0.43 7.73 ± 0.36 6.77 ± 0.47 2.05 ± 0.50 1.43 ± 0.29
-Tocopherol (µmol/mmol) 2.26 ± 0.14 2.74 ± 0.22 2.26 ± 0.13 2.49 ± 0.24 4.13 ± 0.23 2.43 ± 0.23 1.98 ± 0.19* 0.02 ± 0.15*
-Tocopherol (nmol/mmol) 85.3 ± 13.0 93.1 ± 13.4 72.0 ± 15.0 82.2 ± 14.3 273.3 ± 26.1 582.0 ± 68.8 208 ± 25* 505 ± 63*
-Carotene (nmol/mmol) 25.6 ± 3.6 56.6 ± 20.3 20.0 ± 3.2 44.3 ± 19.8 12.0 ± 2.2 35.0 ± 20.2 8.1 ± 1.4 10.9 ± 2.4
-Carotene (nmol/mmol) 4.1 ± 0.9 9.3 ± 3.4 2.9 ± 0.8 5.2 ± 1.7 2.2 ± 0.6 4.0 ± 1.3 0.7 ± 0.2 1.5 ± 0.5
Lycopene (nmol/mmol) 20.5 ± 3.0 51.9 ± 10.9 15.5 ± 3.3 37.1 ± 8.7 10.3 ± 2.0 24.5 ± 5.3 5.1 ± 1.6 15.1 ± 6.1
Lutein (nmol/mmol) 15.4 ± 2.1 18.8 ± 2.8 13.8 ± 1.6 14.7 ± 1.4 9.0 ± 0.8 10.3 ± 1.2 4.8 ± 0.9 4.5 ± 0.8
Cryptoxanthin (nmol/mmol) 21.1 ± 6.4 20.6 ± 4.6 18.9 ± 5.9 15.8 ± 3.7 11.1 ± 3.4 10.3 ± 2.3 6.9 ± 2.2 3.2 ± 1.3
Carotenoids (nmol/mmol) 85.7 ± 11.2 157.1 ± 29.0 71.1 ± 10.3 117.0 ± 24.3 44.6 ± 6.2 84.1 ± 24.4 25.6 ± 4.5 35.2 ± 8.0
#Sum of plasma triacylglycerol, total cholesterol, and phospholipids; *significantly different means by treatment; P < 0.001, unpaired t-test.
Table 3 Fatty acid composition (mol-%, mean ± SEM) of plasma phospholipids in surgical patients before (day 0, fasted) and after surgery (day 1, fasted)
as well as after 5 days of TPN (day 6, end of infusion) with an omega-3-fatty acid-containing lipid emulsion (MLF, n= 17) or an LCT emulsion (n=16)
Day 0 Day 1 Day 6
Fatty acid MLF LCT MLF LCT MLF LCT
16:0 34.80 ± 0.71 34.78 ± 0.80 37.59 ± 0.56 36.66 ± 0.98 33.69 ± 1.10 31.75 ± 1.07
18:0 15.34 ± 0.52 15.72 ± 0.47 14.54 ± 0.57 14.38 ± 0.49 18.08 ± 0.63 16.22 ± 0.51
18:1 11.77 ± 0.81 11.19 ± 0.50 11.10 ± 0.32 11.54 ± 0.34 13.24 ± 0.55 11.16 ± 0.49
18:2 n-6 17.30 ± 0.89 16.97 ± 0.73 16.39 ± 0.73 15.88 ± 0.79 14.99 ± 0.71 * 20.08 ± 1.01*
18:3 n-3 0.51 ± 0.21 0.45 ± 0.25 0.23 ± 0.04 0.34 ± 0.13 0.42 ± 0.08 1.12 ± 0.56
20:3 n-6 1.97 ± 0.14 2.22 ± 0.15 1.69 ± 0.12 2.03 ± 0.20 1.78 ± 0.19 2.04 ± 0.23
20:4 n-6 8.76 ± 0.66 8.31 ± 0.77 8.96 ± 0.56 8.61 ± 0.73 6.21 ± 0.50 6.13 ± 0.60
20:5 n-3 0.57 ± 0.07 0.86 ± 0.13 0.65 ± 0.06 0.66 ± 0.10 2.07 ± 0.33 * 0.77 ± 0.20*
22:6 n-3 5.29 ± 0.60 5.01 ± 0.46 5.05 ± 0.48 5.67 ± 0.66 5.68 ± 0.98 5.72 ± 0.67
n-6# 28.03 ± 1.18 27.50 ± 1.13 27.03 ± 0.74 26.52 ± 1.18 22.99 ± 1.06 28.25 ± 1.70
n-3§ 6.37 ± 0.76 6.32 ± 0.70 5.93 ± 0.50 6.68 ± 0.73 8.17 ± 1.09 7.61 ± 1.26
n-6:n-3 ratio 5.27 ± 0.55 5.14 ± 0.58 5.12 ± 0.50 4.82 ± 0.70 3.66 ± 0.47 4.38 ± 0.38
#18:2 n-6 20:3 n-6 20:4 n-6; §18:3 n-3 20:5 n-3 22:6 n-3; *significantly different means by treatment, P 0.05; unpaired t-test.
As a measure of in vivo oxidation processes, plasma total
COP concentrations were analysed. The results show only
small changes by time (Table 6). The insignificant differ-
ences between groups existed on all blood sampling points.
Due to lower plasma total cholesterol concentrations on
days 1 and 6 (versus day 0), the COP: cholesterol ratio
increased to a similar extent in both groups.
Discussion
The plasma lipid concentrations were not significantly dif-
ferent between groups and confirm an effective hydolysis
and plasma clearance of the administered MLF emulsion
(2). Plasma phospholipids were significantly enriched with
EPA after 5 days of TPN with the MLF fat emulsion
( 1.62 mol-%, day 6 vs day 1); the mean increase in DHA
amounting to 0.63 mol-% did not reach statistical signi-
ficance. Using a comparable study design, Morlion and
coworker (8) reported a similar enrichment of EPA in plasma
phospholipids after 5 days of infusion of a fish oil-containing
fat emulsion. The contribution of soybean oil to the adminis-
tered MLF fat emulsion amounted to 40% of the total fat
content; consequently, the linoleic acid content (linoleic acid
as the most important fatty acid of soybean oil) was approxi-
mately 60% lower compared to the LCT emulsion (Table 2).
As expected, LCT infusion provoked significantly higher
linoleic acid concentrations in plasma phospholipids than
MLF infusion (Table 3). For the differences in the calcula-
ted sums of the n-3 and n-6 fatty acids no statistical signi-
ficance between groups could be obtained. Thus, the lower
n-6:n-3 ratio in the MLF group after 5 days of TPN was not
significantly different from that found for the LCT group.
However, Lienhard et al. (28) demonstrated, for the patients
of the present investigation, that the infused amount of n-3
fatty acids was sufficient to reveal biological effects.
Patients with major surgery undergo a special metabolic
stress situation that is coupled with an increased production
of radicals and other highly reactive compounds mainly
originating from immunologically active cells (29, 30). In
particular, in dealing with the problem of ischemia reper-
fusion injury supplementation with antioxidants such as
vitamin E was shown to reduce the production of free radi-
cals and lipid peroxidation products and to decrease cell
damage, indicating a clear benefit for the clinical outcome of
the patients (30–33). It can be deduced that the preoperative
antioxidant status is as important as its development after
surgery. Moreover, intravenous administration of lipid emul-
sions containing a high amount of PUFA and an insufficient
protection by antioxidants may provoke undesirable autoxi-
dation processes (2). The susceptability of fatty acids for
oxidation strongly increases with the number of double
bonds. Hence, the highly unsaturated fatty acids EPA and
DHA from fish oil reveal a high risk for oxidative damage
and deserves a careful handling (e.g. light protection) and a
sufficient content of antioxidative substances as well.
Dupont et al. (15) demonstrated that a similar fish oil-
containing fat emulsion (MLF 541, 200 mg/l -tocopherol)
was efficiently resistent to in vitro oxidation. They found
comparable results for the oxidative stability with the MLF
emulsion and the MCT/LCT (1/1) emulsion, while the soy-
bean oil fat emulsion (LCT) with low -tocopherol content
(15 mg/l) was shown to be much more sensitive to in vitro
peroxidation. The authors concluded that the oxidative risk
by fish oil is efficiently counteracted by the -tocopherol
enrichment (15). However, at rather high concentrations the
antioxidant activity of -tocopherol can be reversed to a
prooxidant effect in certain in vitro models (34, 35), indica-
ting an upper limit for the -tocopherol supplementation of
lipid emulsions. According to the findings of Dupont (16),
this limit may not be exceeded by addition of 200 mg/l
-tocopherol.
Regarding the essentiality of vitamin E, -tocopherol
shows a much lower biological acitivity than -tocopherol
after dietary intake (based on bioassays in animals) (36)
but reveals the highest antioxidant efficacy among the
tocopherol homologues when tested in foodstuff (37).
However, Traber et al. (38) showed that after stopping the
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Table 6 Cholesterol oxidations products (COP; µmol/l, mean ± SEM), total cholesterol (µmmol/l) and COP:cholesterol ratio (mol/mmol) in the plasma of
surgical patients before (day 0, fasted) and after surgery (day 1, fasted) as well as after 5 days of TPN (day 6, end of infusion) with an omega-3-fatty
acid-containing lipid emulsion (MLF; n=9) or an LCT emulsion (n=6)
Day 0 Day 1 Day 6
MLF LCT MLF LCT MLF LCT
7 -Hydroxycholesterol (µmol/l) 12.50 ± 1.34 10.33 ± 0.58 12.07 ± 1.05 10.46 ± 0.50 11.35 ± 1.21 10.32 ± 0.31
7 -Hydroxycholesterol (µmol/l) 13.51 ± 1.33 11.44 ± 0.58 13.26 ± 0.99 11.52 ± 0.56 12.56 ± 1.26 11.55 ± 0.27
Cholesterol- -epoxide (µmol/l) 3.16 ± 0.39 2.81 ± 0.51 3.61 ± 0.46 3.05 ± 0.41 3.94 ± 0.64 3.26 ± 0.35
Cholesterol- -epoxide (µmol/l) 1.59 ± 0.32 0.95 ± 0.13 1.27 ± 0.14 1.07 ± 0.06 1.58 ± 0.30 1.02 ± 0.12
Cholestanetriol (µmol/l) 0.52 ± 0.10 0.45 ± 0.08 0.38 ± 0.08 0.50 ± 0.12 0.62 ± 0.10 0.41 ± 0.09
6-Ketocholestanol (µmol/l) 0.04 ± 0.02 0.04 ± 0.02 0.05 ± 0.02 0.03 ± 0.02 0.31 ± 0.16 0.03 ± 0.02
7-Ketocholesterol (µmol/l) 13.74 ± 1.08 12.51 ± 1.25 14.65 ± 1.27 13.00 ± 0.79 14.56 ± 1.56 13.47 ± 0.58
25-Hydroxycholesterol (µmol/l) 0.87 ± 0.11 0.79 ± 0.08 0.62 ± 0.12 0.65 ± 0.14 0.57 ± 0.08 0.79 ± 0.15
COP (µmol/l) 45.93 ± 3.71 39.3 ± 22.71 45.90 ± 3.44 40.26 ± 2.00 45.50 ± 4.22 40.86 ± 1.32
Total cholesterol (mmol/l) 5.55 ± 0.39 5.05 ± 0.33 2.97 ± 0.31 2.78 ± 0.24 3.50 ± 0.18 3.32 ± 0.27
COP:cholesterol ratio (µmol/mmol) 8.18 ± 0.86 8.48 ± 0.94 18.43 ± 2.18 15.40 ± 1.40 13.45 ± 1.58 12.20 ± 0.62
infusion of soybean oil-based lipid emulsions the elevated
plasma -tocopherol levels could not be maintained. They
supposed that -tocopherol is rapidly taken up by the liver
and not further released via VLDL secretion.
They also found that the TG emulsion particles enrich
-tocopherol by depleting endogenous lipoproteins (LDL).
Further, the elevated pentane exhalation in patients on total
parenteral nutrition with soybean oil-based lipid emulsions
hints to an incomplete protection of PUFA by -tocopherol
(17, 18). It seems likely that even high amounts of non- -
tocopherol do not equal -tocopherol in parenteral nutrition
(38–40). Finally, less is known about the biological conse-
quences of a non- -tocopherol enrichment of cell membranes
(40). Only after a sufficient supplementation of -tocopherol,
also considering the ratio of -tocopherol to non- -toco-
pherol, plasma levels of -tocopherol could be distinctly
enhanced and maintained after stopping the infusion (38).
Intravenous provision of the recommended dietary allow-
ance (RDA) of -tocopherol was already shown to be unable
to stop the decrease in plasma or red blood cell -tocopherol
concentrations in different patients receiving TPN (39, 40).
For the purpose of parenteral nutrition a sufficient intake
of vitamin E and other antioxidants is better judged on
their plasma levels. Regarding the results of prospective
studies on the preventive effect of antioxidants, i.e., a low
risk for coronary heart disease and certain types of cancer,
-tocopherol, vitamin C, and -carotene plasma concentra-
tions of >30 µmol/l, >50 µmol/l, and >0.4 µmol/l respec-
tively were regarded as optimum levels (41). In the VERA
study (Germany), low plasma concentrations were identified
by means of the 2.5th percentiles of a reference sample with
values <17.7 µmol/l for -tocopherol, <36.8 µmol/l for vita-
min C, and <0.18 µmol/l for -carotene (42). Evaluating the
plasma antioxidant concentrations before surgery (day 0;
Table 4), the average of the patients laid below the given
optimum values, but nearly all patients exceeded the 2.5th
percentiles. After surgery (day 1), the concentrations of all
antioxidants were drastically reduced. Due to the concomit-
tantly reduced plasma lipid concentrations the decreases
were much smaller or even disappeared when the lipid-solu-
ble antioxidants were corrected for the plasma lipid content
(Table 5); this is especially true for -tocopherol.
During the 5 day TPN period, - and -tocopherol con-
centrations (in µmol/l, Table 4) increased in both TPN treat-
ment groups. The changes in plasma concentrations were in
accordance to the proportion of the tocopherol homologues
in the two fat emulsions.
However, after correction for plasma lipids the -toco-
pherol values in the LCT group did not change at all during
TPN (Table 5), indicating that the (-tocopherol content of
the LCT emulsion was insufficient to reconstitute preopera-
tive plasma values or to reach recommended plasma con-
centrations (see above). In contrast, infusion of the MLF
emulsion resulted in desirable plasma -tocopherol concen-
trations. A supplementation dose of 200 mg -tocopherol
per day was already reported to normalize plasma -toco-
pherol values in patients on long-term home parenteral
nutrition (19).
On average, the patients’ initial plasma concentrations of
-carotene, lycopene, lutein, and cryptoxanthin were rather
low, judged by means of reported ‘typical’ plasma concen-
trations (43). This is also true for selenium (44). Due to the
ascorbyl palmitate supplementation of the MLF emulsion,
the fall in plasma vitamin C concentrations by surgical treat-
ment could be stopped in the patients of the MLF group
only. Contrary to this, the plasma carotenoid concentrations
continously decreased in both groups, caused by the lack of
intake during the observational period and the metabolic
stress situation. It is worth mentioning that carotenoids – as
well as tocopherols – may not only be involved in the
management of oxidative stress but may also reveal effects
on the immune system at a cellular level (36, 45).
Surprisingly, the high plasma -tocopherol concentrations
in the MLF group on day 6 were not accompanied by
enhanced TAC values (Table 4). However, it has to be
stressed that the TAC is strongly affected by other plasma
antioxidants of endogene origin, i.e., uric acid, bilirubin, and
protein sulfhydryl groups, not determined here (26, 46).
TAC values before surgery were at the lower physiological
range of 414.7 ± 77.3 µmol/l (26).
As suggested by Jialal et al. (47), measurement of COP in
plasma or lipoproteins may serve as an index of in vivo oxi-
dation reactions. The results provide better information than
given by in vitro assays, e.g. the determination of the oxida-
tive susceptability of LDL in response to the addition of an
oxidant or the determination of the total antioxidant capacity
in serum samples. The reported plasma COP concentrations
gave no distinct hint for enhanced in vivo oxidation pro-
cesses after administration of the MLF fat emulsion. The
COP concentrations were rather stable throughout the study
(Table 6). Not even the surgical treatment seemed to be
followed by increased plasma cholesterol oxidation (day 1
vs day 0). However, plasma concentrations may not reflect
the situation in target tissues after surgery. Besides, it should
be mentioned that, postoperatively, plasma cholesterol con-
centrations decreased, resulting in higher COP:cholesterol
ratios. Since it is suspected that only highly COP-enriched
lipoprotein (LDL) particles are atherogenic (48), the situa-
tion may have been worsened by surgery. Compared to
healthy young subjects revealing mean plasma COP concen-
trations of 31.2 ± 0.6 µmol/l (49), the patients had elevated
plasma COP values before surgical treatment. However,
values of a well-matched control group are not available.
In conclusion, the -tocopherol enrichment of the omega-
3-fatty acid-containing fat emulsion was able to normalize
low plasma values in patients after surgery. Without sup-
plementation, plasma concentrations of all carotenoids, vita-
min C, and selenium decreased by surgery and the fall
continued over the following 5 days of TPN. However, the
total plasma COP concentrations as a measure of autoxida-
tion processes in vivo were neither affected by surgery nor
by TPN. While the need for -tocopherol enrichment of
lipid emulsions seems generally accepted, the supplemen-
tation of other antioxidants within TPN needs further evalu-
ation since the decrease in serum total antioxidant capacity
could not be stopped by -tocopherol supplementation only.
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